Description
Class A61P : THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
Subclass 1/06: Drugs for disorders of the alimentary tract or the digestive system Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
Class A61P : THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
Subclass 1/06: Drugs for disorders of the alimentary tract or the digestive system Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
Patent # | Title | Filing Date | Issue Date | Patent Owner |
---|---|---|---|---|
11925688 | Compositions and methods relating to salts of specialized pro-resolving mediators | Oct 01, 21 | Mar 12, 24 | Thetis Pharmaceuticals LLC |
11786562 | Bacteriotherapy | Apr 19, 17 | Oct 17, 23 | Genome Research Limited |
11642339 | Methods of treating symptoms of gastroparesis using velusetrag | Jul 30, 18 | May 09, 23 | Theravance Biopharma R&D IP, LLC; ALFASIGMA S.P.A.; |
11446294 | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy | Sep 18, 19 | Sep 20, 22 | Not available |
11337990 | Human milk oligosaccharides to promote growth of beneficial bacteria | Dec 22, 11 | May 24, 22 | Abbott Laboratories |
11191840 | Compositions and methods relating to salts of specialized pro-resolving mediators | Nov 28, 18 | Dec 07, 21 | Thetis Pharmaceuticals LLC |
11179427 | Baby food composition comprising viable propionic acid-producing bacteria | Jan 18, 19 | Nov 23, 21 | ETH Zurich |
11135298 | Compositions and methods relating to salts of specialized pro-resolving mediators | Aug 08, 19 | Oct 05, 21 | Thetis Pharmaceuticals LLC |
10632142 | Treatment of colitis with resistant starch | Feb 08, 19 | Apr 28, 20 | McPharma Biotech Inc. |
10420843 | Compositions and methods relating to salts of specialized pro-resolving mediators | Nov 28, 17 | Sep 24, 19 | Thetis Pharmaceuticals LLC |
10314859 | Use of gastrointestinally administered porous enteron sorbent polymers to prevent or treat radiation induced mucositis, esophagitis, enteritis, colitis, and gastrointestinal acute radiation syndrome | Feb 02, 18 | Jun 11, 19 | CYTOSORBENTS CORPORATION |
10130719 | Compositions and methods relating to salts of specialized pro-resolving mediators | Jun 02, 17 | Nov 20, 18 | Thetis Pharmaceuticals LLC |
RE46417 | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands | Feb 09, 16 | May 30, 17 | ALMIRALL, S.A. |
9457054 | strain for prophylaxis and treatment of gastro-intestinal conditions | Mar 17, 11 | Oct 04, 16 | BAYER CROPSCIENCE LP |
8772482 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use | Jun 17, 11 | Jul 08, 14 | LEXICON PHARMACEUTICALS, INC. |
8372973 | Prokineticin 1 receptor antagonists | Dec 16, 10 | Feb 12, 13 | JANSSEN PHARMACEUTICA NV |
8362247 | Prokineticin 1 receptor antagonists | May 23, 11 | Jan 29, 13 | JANSSEN PHARMACEUTICA NV |
8324380 | Amino-heteroaryl-containing prokineticin 1 receptor antagonists | Oct 23, 08 | Dec 04, 12 | JANSSEN PHARMACEUTICA NV |
7968710 | Prokineticin 1 receptor antagonists | Mar 14, 06 | Jun 28, 11 | JANSSEN PHARMACEUTICA NV |
7902358 | Prokineticin 1 receptor antagonists | Dec 28, 06 | Mar 08, 11 | JANSSEN PHARMACEUTICA NV |
Publication # | Title | Filing Date | Pub Date | Patent Owner |
---|---|---|---|---|
2024/0156,880 | BACTERIOTHERAPY | Aug 09, 23 | May 16, 24 | Not available |
2024/0108,610 | RECTAL ADMINISTRATION OF ROFLUMILAST FOR THE TREATMENT OF CROHN'S DISEASE | Sep 08, 23 | Apr 04, 24 | Not available |
2019/0277,833 | ANTI-METHANOGENIC COMPOSITIONS | May 12, 17 | Sep 12, 19 | Not available |
2011/0282,464 | Reactive Surgical Implants | May 12, 10 | Nov 17, 11 | COVIDIEN LP, SOFRADIM PRODUCTION, |
2011/0251,233 | FORMULATION FOR THE BUCCAL TRANSMUCOSAL ADMINISTRATION OF SETRONS | Dec 17, 09 | Oct 13, 11 | Not available |
2010/0303,763 | METHOD FOR DECREASING ABDOMINAL GIRTH BY ADMINISTERING A BIFIDOBACTERIUM BACTERIA | Dec 19, 08 | Dec 02, 10 | COMPAGNIE GERVAIS DANONE |
Upgrade to the Professional Level to view Top Owners for this Subclass.Learn More |
---|